Drugs / AVZO-021
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06998407 | Aug 2025 → Aug 2028 expected | hormone receptor-positive breast cancer | Avenzo Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05867251 | Aug 2023 → Jan 2028 expected | endometrial cancer, fallopian tube cancer, hormone receptor-positive breast cancer, malignant epithelial tumor of ovary +2 | Avenzo Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVZO-021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05867251 ↗ |
| Action | Inhibit | “AVZO-021 is a selective and potent cyclin-dependent kinase 2 (CDK2) inhibitor” NCT05867251 ↗ |
| Route | Oral | “AVZO-021 is an oral medication” NCT05867251 ↗ |
| Target | CDK2 | “AVZO-021 is a selective and potent cyclin-dependent kinase 2 (CDK2) inhibitor” NCT05867251 ↗ |